Dr. Aaron G.L. Fletcher has served as a director of Actuate Therapeutics since April 2015 and is Chairperson of the Board and chair of its nominating and corporate governance committee. He is the founder and President of Bios Research, a healthcare-focused financial services firm he has led since 2012, and has worked as an independent consultant in the biotechnology and healthcare equity industry for over a decade. Through affiliated Bios Equity funds he is one of Actuate's largest shareholders. He currently serves on the boards of Cognition Therapeutics, Inc. and ONL Therapeutics, Inc., and has previously served on the boards of TFF Pharmaceuticals, Cue Biopharma, Lung Therapeutics, Rein Therapeutics (formerly Aileron Therapeutics), AbiliTech Medical and SWK Holdings. He is also a visiting professor at Dallas Baptist University and earned his Ph.D. in Biochemistry from Colorado State University.